title: Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility.
abstract: The versatility of NMR and its broad applicability to several stages in the drug discovery process is well known and generally considered one of the major strengths of NMR (Pellecchia et al., Nature Rev Drug Discov 1:211-219, 2002; Stockman and Dalvit, Prog Nucl Magn Reson Spectrosc 41:187-231, 2002; Lepre et al., Comb Chem High throughput screen 5:583-590, 2002; Wyss et al., Curr Opin Drug Discov Devel 5:630-647, 2002; Jahnke and Widmer, Cell Mol Life Sci 61:580-599, 2004; Huth et al., Methods Enzymol 394:549-571, 2005b; Klages et al., Mol Biosyst 2:318-332, 2006; Takeuchi and Wagner, Curr Opin Struct Biol 16:109-117, 2006; Zartler and Shapiro, Curr Pharm Des 12:3963-3972, 2006). Indeed, NMR is the only biophysical technique which can detect and quantify molecular interactions, and at the same time provide detailed structural information with atomic level resolution. NMR should therefore be ideally suited and widely requested as a tool for drug discovery research, and numerous examples of drug discovery projects which have substantially benefited from NMR contributions or were even driven by NMR have been described in the literature. However, not all pharmaceutical companies have rigorously implemented NMR as integral tool of their research processes. Some companies invest with limited resources, and others do not use biomolecular NMR at all. This discrepancy in assessing the value of a technology is striking, and calls for clarification--under which circumstances can NMR provide added value to the drug discovery process? What kind of contributions can NMR make, and how is it implemented and integrated for maximum impact? This perspectives article suggests key areas of impact for NMR, and a model of integrating NMR with other technologies to realize synergies and maximize their value for drug discovery.
authors: Novartis Institutes for BioMedical Research, Discovery Technologies, Basel 4002, Switzerland. wolfgang.jahnke@novartis.com
authors: Wolfgang
authors: W
authors: Jahnke
mesh_terms: D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004345:Drug Industry; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods*; D012984:Software
references: Comb Chem High Throughput Screen. 2002 Dec;5(8):583-90
references: 12470255
references: Angew Chem Int Ed Engl. 2005 Jul 4;44(27):4172-5
references: 15929149
references: Analyst. 2007 Jul;132(7):693-705
references: 17657909
references: Nat Rev Drug Discov. 2002 Mar;1(3):211-9
references: 12120505
references: Science. 1996 Nov 29;274(5292):1531-4
references: 8929414
references: Curr Opin Struct Biol. 2006 Feb;16(1):109-17
references: 16427776
references: J Am Chem Soc. 2005 Jan 12;127(1):217-24
references: 15631471
references: Curr Opin Drug Discov Devel. 2005 Jul;8(4):513-9
references: 16022188
references: Drug Discov Today. 2003 Sep 1;8(17):803-10
references: 12946643
references: J Med Chem. 2007 May 3;50(9):2137-43
references: 17394300
references: Nature. 2005 Jun 2;435(7042):677-81
references: 15902208
references: Curr Drug Discov Technol. 2006 Jun;3(2):115-24
references: 16925519
references: Cell Mol Life Sci. 2004 Mar;61(5):580-599
references: 15004697
references: Chembiochem. 2002 Mar 1;3(2-3):167-73
references: 11921394
references: J Am Chem Soc. 2004 Mar 3;126(8):2390-8
references: 14982445
references: Curr Opin Drug Discov Devel. 2002 Jul;5(4):630-47
references: 12197321
references: Nat Rev Drug Discov. 2007 Mar;6(3):211-9
references: 17290284
references: Curr Opin Drug Discov Devel. 2007 May;10(3):289-97
references: 17554855
references: Curr Pharm Des. 2006;12(31):3963-72
references: 17100607
references: Chemistry. 2006 Mar 20;12(10):2658-62
references: 16121405
references: Methods Enzymol. 2005;394:549-71
references: 15808237